NCT00848601View on ClinicalTrials.gov

Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Prostate CancerNon-Hodgkins Lymphoma
Interventions
DRUG

SGI-1776

Starting dose 100 mg (total daily dose) administer as 50 mg every 12 hours for 14 days of a 21-day cycle, dose escalation in successive cohorts until progression or toxicity develops

Trial Locations (3)

78229

Cancer Therapy Research Center, San Antonio

90095-1678

UCLA, Los Angeles

SM2 5PT

Royal Marsden Hospital, Sutton

Sponsors
All Listed Sponsors
lead

Astex Pharmaceuticals, Inc.

INDUSTRY